請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/49362
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 莊榮輝(Rong-Huay Juang) | |
dc.contributor.author | Jhih-Shiang Dong | en |
dc.contributor.author | 董志祥 | zh_TW |
dc.date.accessioned | 2021-06-15T11:25:18Z | - |
dc.date.available | 2019-10-05 | |
dc.date.copyright | 2016-10-05 | |
dc.date.issued | 2016 | |
dc.date.submitted | 2016-08-18 | |
dc.identifier.citation | 1. Gendon Iu, Z., Influenza pandemic: hypotheses and facts. Zh Mikrobiol Epidemiol Immunobiol, 2008(5): p. 109-18.
2. Lupiani, B. and S.M. Reddy, The history of avian influenza. Comp Immunol Microbiol Infect Dis, 2009. 32(4): p. 311-23. 3. Kawaoka, Y., S. Krauss, and R.G. Webster, Avian-to-human transmission of the PB1 gene of influenza A viruses in the 1957 and 1968 pandemics. J Virol, 1989. 63(11): p. 4603-8. 4. Subbarao, K. and J. Katz, Avian influenza viruses infecting humans. Cell Mol Life Sci, 2000. 57(12): p. 1770-84. 5. Kilbourne, E.D., et al., Immunologic response to the influenza virus neuraminidase is influenced by prior experience with the associated viral hemagglutinin. I. Studies in human vaccinees. J Immunol, 1987. 138(9): p. 3010-3. 6. Tong, S., et al., New world bats harbor diverse influenza A viruses. PLoS Pathog, 2013. 9(10): p. e1003657. 7. Z P Ye, N.W.B., and R R Wagner, Transcription-inhibition and RNA-binding domains of influenza A virus matrix protein mapped with anti-idiotypic antibodies and synthetic peptides. J Virol., 1989. 63(9): p. 3586-3594. 8. Pleschka, S., Overview of influenza viruses. Curr Top Microbiol Immunol, 2013. 370: p. 1-20. 9. Kapoor, S. and K. Dhama, Properties of Influenza Viruses. 2014: p. 7-13. 10. Chen W1, C.P., Malide D, Gibbs J, Schubert U, Bacik I, Basta S, O'Neill R, Schickli J, Palese P, Henklein P, Bennink JR, Yewdell JW., A novel influenza A virus mitochondrial protein that induces cell death. Nature Medicine, 2001. 7(12). 11. Gibbs, J.S., et al., The influenza A virus PB1-F2 protein targets the inner mitochondrial membrane via a predicted basic amphipathic helix that disrupts mitochondrial function. J Virol, 2003. 77(13): p. 7214-24. 12. Chanturiya, A.N., et al., PB1-F2, an influenza A virus-encoded proapoptotic mitochondrial protein, creates variably sized pores in planar lipid membranes. J Virol, 2004. 78(12): p. 6304-12. 13. Inglis, S.C. and C.M. Brown, Spliced and unspliced RNAs encoded by virion RNA segment 7 of influenza virus. Nucleic Acids Res, 1981. 9(12): p. 2727-40. 14. Brown, E.G., Influenza virus genetics. Biomed Pharmacother, 2000. 54(4): p. 196-209. 15. Plotch, S.J., et al., A unique cap(m7GpppXm)-dependent influenza virion endonuclease cleaves capped RNAs to generate the primers that initiate viral RNA transcription. Cell, 1981. 23(3): p. 847-58. 16. Rameix-Welti, M.A., et al., Avian Influenza A virus polymerase association with nucleoprotein, but not polymerase assembly, is impaired in human cells during the course of infection. J Virol, 2009. 83(3): p. 1320-31. 17. Mair, C.M., et al., Receptor binding and pH stability - how influenza A virus hemagglutinin affects host-specific virus infection. Biochim Biophys Acta, 2014. 1838(4): p. 1153-68. 18. Naffakh, N., et al., Host restriction of avian influenza viruses at the level of the ribonucleoproteins. Annu Rev Microbiol, 2008. 62: p. 403-24. 19. Air, G.M., Influenza neuraminidase. Influenza Other Respir Viruses, 2012. 6(4): p. 245-56. 20. Das, K., et al., Structures of influenza A proteins and insights into antiviral drug targets. Nat Struct Mol Biol, 2010. 17(5): p. 530-8. 21. Marc, D., Stop-codon variations in non-structural protein NS1 of avian influenza viruses. Virulence, 2016: p. 0. 22. Lakadamyali, M., M.J. Rust, and X. Zhuang, Endocytosis of influenza viruses. Microbes Infect, 2004. 6(10): p. 929-36. 23. Hamilton, B.S., G.R. Whittaker, and S. Daniel, Influenza virus-mediated membrane fusion: determinants of hemagglutinin fusogenic activity and experimental approaches for assessing virus fusion. Viruses, 2012. 4(7): p. 1144-68. 24. Huang, Q., et al., Early steps of the conformational change of influenza virus hemagglutinin to a fusion active state. Biochimica et Biophysica Acta (BBA) - Biomembranes, 2003. 1614(1): p. 3-13. 25. Wu, W.W. and N. Pante, The directionality of the nuclear transport of the influenza A genome is driven by selective exposure of nuclear localization sequences on nucleoprotein. Virol J, 2009. 6: p. 68. 26. Ulmanen, I., B.A. Broni, and R.M. Krug, Role of two of the influenza virus core P proteins in recognizing cap 1 structures (m7GpppNm) on RNAs and in initiating viral RNA transcription. Proc Natl Acad Sci U S A, 1981. 78(12): p. 7355-9. 27. Newcomb, L.L., et al., Interaction of the influenza a virus nucleocapsid protein with the viral RNA polymerase potentiates unprimed viral RNA replication. J Virol, 2009. 83(1): p. 29-36. 28. Nemeroff, M.E., et al., Influenza virus NS1 protein interacts with the cellular 30 kDa subunit of CPSF and inhibits 3'end formation of cellular pre-mRNAs. Mol Cell, 1998. 1(7): p. 991-1000. 29. Shimizu, K., et al., Influenza virus inhibits cleavage of the HSP70 pre-mRNAs at the polyadenylation site. Virology, 1999. 254(2): p. 213-9. 30. Neumann, G., M.T. Hughes, and Y. Kawaoka, Influenza A virus NS2 protein mediates vRNP nuclear export through NES-independent interaction with hCRM1. Embo j, 2000. 19(24): p. 6751-8. 31. Rossman, J.S. and R.A. Lamb, Influenza virus assembly and budding. Virology, 2011. 411(2): p. 229-36. 32. Chen, Y., et al., Human infections with the emerging avian influenza A H7N9 virus from wet market poultry: clinical analysis and characterisation of viral genome. The Lancet, 2013. 381(9881): p. 1916-1925. 33. Chang, S.Y., et al., The first case of H7N9 influenza in Taiwan. Lancet, 2013. 381(9878): p. 1621. 34. Dortmans, J.C., et al., Adaptation of novel H7N9 influenza A virus to human receptors. Sci Rep, 2013. 3: p. 3058. 35. Gao, R., et al., Human infection with a novel avian-origin influenza A (H7N9) virus. N Engl J Med, 2013. 368(20): p. 1888-97. 36. Xiong, X., et al., Receptor binding by an H7N9 influenza virus from humans. Nature, 2013. 499(7459): p. 496-9. 37. Shi, Y., et al., Structures and receptor binding of hemagglutinins from human-infecting H7N9 influenza viruses. Science, 2013. 342(6155): p. 243-247. 38. Steel, J., et al., Transmission of influenza virus in a mammalian host is increased by PB2 amino acids 627K or 627E/701N. PLoS Pathog, 2009. 5(1): p. e1000252. 39. Liu, Q., et al., Genomic signature and protein sequence analysis of a novel influenza A (H7N9) virus that causes an outbreak in humans in China. Microbes Infect, 2013. 15(6-7): p. 432-9. 40. Yen, H.L., et al., Resistance to neuraminidase inhibitors conferred by an R292K mutation in a human influenza virus H7N9 isolate can be masked by a mixed R/K viral population. MBio, 2013. 4(4). 41. Wu, Y., et al., Characterization of two distinct neuraminidases from avian-origin human-infecting H7N9 influenza viruses. Cell Res, 2013. 23(12): p. 1347-55. 42. Bi, Y., et al., Changes in the length of the neuraminidase stalk region impact H7N9 virulence in mice. J Virol, 2015. 90(4): p. 2142-9. 43. Munier, S., et al., A genetically engineered waterfowl influenza virus with a deletion in the stalk of the neuraminidase has increased virulence for chickens. J Virol, 2010. 84(2): p. 940-52. 44. Barman, S., et al., Role of transmembrane domain and cytoplasmic tail amino acid sequences of influenza a virus neuraminidase in raft association and virus budding. J Virol, 2004. 78(10): p. 5258-69. 45. Jin, H., et al., Influenza virus hemagglutinin and neuraminidase cytoplasmic tails control particle shape. Embo j, 1997. 16(6): p. 1236-47. 46. Krogh, A., et al., Predicting transmembrane protein topology with a hidden Markov model: application to complete genomes. J Mol Biol, 2001. 305(3): p. 567-80. 47. Moller, S., M.D. Croning, and R. Apweiler, Evaluation of methods for the prediction of membrane spanning regions. Bioinformatics, 2001. 17(7): p. 646-53. 48. Blok, J. and G.M. Air, Block deletions in the neuraminidase genes from some influenza A viruses of the N1 subtype. Virology, 1982. 118(1): p. 229-34. 49. Els, M.C., et al., An 18-amino acid deletion in an influenza neuraminidase. Virology, 1985. 142(2): p. 241-7. 50. Cuff, J.A., et al., JPred: a consensus secondary structure prediction server. Bioinformatics, 1998. 14(10): p. 892-3. 51. Harris, A., et al., Influenza virus pleiomorphy characterized by cryoelectron tomography. Proc Natl Acad Sci U S A, 2006. 103(50): p. 19123-7. 52. Murti, K.G. and R.G. Webster, Distribution of hemagglutinin and neuraminidase on influenza virions as revealed by immunoelectron microscopy. Virology, 1986. 149(1): p. 36-43. 53. Burmeister, W.P., R.W. Ruigrok, and S. Cusack, The 2.2 A resolution crystal structure of influenza B neuraminidase and its complex with sialic acid. Embo j, 1992. 11(1): p. 49-56. 54. Russell, R.J., et al., The structure of H5N1 avian influenza neuraminidase suggests new opportunities for drug design. Nature, 2006. 443(7107): p. 45-9. 55. Hirst, G.K., The agglutination of red cells by allantoic fluid of chick embryos infected with influenza virus. Science, 1941. 94(2427): p. 22-3. 56. Gottschalk, A., Neuraminic acid; the functional group of some biologically active mucoproteins. Yale J Biol Med, 1956. 28(5): p. 525-37. 57. Laver, W.G., Crystallization and peptide maps of neuraminidase 'heads' from H2N2 and H3N2 influenza virus strains. Virology, 1978. 86(1): p. 78-87. 58. Baum, L.G. and J.C. Paulson, The N2 neuraminidase of human influenza virus has acquired a substrate specificity complementary to the hemagglutinin receptor specificity. Virology, 1991. 180(1): p. 10-5. 59. Kobasa, D., et al., Amino acid residues contributing to the substrate specificity of the influenza A virus neuraminidase. J Virol, 1999. 73(8): p. 6743-51. 60. Mochalova, L., et al., Oligosaccharide specificity of influenza H1N1 virus neuraminidases. Arch Virol, 2007. 152(11): p. 2047-57. 61. Drzeniek R, S.J., Rott R., Characterization of neuraminidases from myxoviruses. Biochim Biophys Acta, 1966. 128: p. 547-558. 62. Wohlbold, T.J. and F. Krammer, In the shadow of hemagglutinin: a growing interest in influenza viral neuraminidase and its role as a vaccine antigen. Viruses, 2014. 6(6): p. 2465-94. 63. Smith, B.J., et al., Structure of a calcium-deficient form of influenza virus neuraminidase: implications for substrate binding. Acta Crystallogr D Biol Crystallogr, 2006. 62(Pt 9): p. 947-52. 64. Saladino, R., et al., Current advances in anti-influenza therapy. Curr Med Chem, 2010. 17(20): p. 2101-40. 65. Mitrasinovic, P.M., Advances in the structure-based design of the influenza A neuraminidase inhibitors. Curr Drug Targets, 2010. 11(3): p. 315-26. 66. De Clercq, E., The next ten stories on antiviral drug discovery (part E): advents, advances, and adventures. Med Res Rev, 2011. 31(1): p. 118-60. 67. Kiso, M., et al., Efficacy of the new neuraminidase inhibitor CS-8958 against H5N1 influenza viruses. PLoS Pathog, 2010. 6(2): p. e1000786. 68. Kohno, S., et al., Efficacy and safety of intravenous peramivir for treatment of seasonal influenza virus infection. Antimicrob Agents Chemother, 2010. 54(11): p. 4568-74. 69. Weight, A.K., et al., Attaching zanamivir to a polymer markedly enhances its activity against drug-resistant strains of influenza a virus. J Pharm Sci, 2011. 100(3): p. 831-5. 70. Saito, T., et al., Antigenicity of the N8 influenza A virus neuraminidase: existence of an epitope at the subunit interface of the neuraminidase. J Virol, 1994. 68(3): p. 1790-6. 71. Webster, R.G., V.S. Hinshaw, and W.G. Laver, Selection and analysis of antigenic variants of the neuraminidase of N2 influenza viruses with monoclonal antibodies. Virology, 1982. 117(1): p. 93-104. 72. Gulati, U., et al., Antibody epitopes on the neuraminidase of a recent H3N2 influenza virus (A/Memphis/31/98). J Virol, 2002. 76(23): p. 12274-80. 73. Webster, R.G., P.A. Reay, and W.G. Laver, Protection against lethal influenza with neuraminidase. Virology, 1988. 164(1): p. 230-7. 74. Eichelberger, M., et al., FDA/NIH/WHO public workshop on immune correlates of protection against influenza A viruses in support of pandemic vaccine development, Bethesda, Maryland, US, December 10-11, 2007. Vaccine, 2008. 26(34): p. 4299-303. 75. Bright, R.A., et al., WHO meeting on the role of neuraminidase in inducing protective immunity against influenza infection, Vilamoura, Portugal, September 14, 2008. Vaccine, 2009. 27(45): p. 6366-9. 76. Webster, R.G., et al., Antigenic structure and variation in an influenza virus N9 neuraminidase. J Virol, 1987. 61(9): p. 2910-6. 77. Wohlbold, T.J., et al., Hemagglutinin stalk- and neuraminidase-specific monoclonal antibodies protect against lethal H10N8 influenza virus infection in mice. J Virol, 2016. 90(2): p. 851-61. 78. Nuss, J.M., P.B. Whitaker, and G.M. Air, Identification of critical contact residues in the NC41 epitope of a subtype N9 influenza virus neuraminidase. Proteins, 1993. 15(2): p. 121-32. 79. Webster, R.G., L.E. Brown, and W.G. Laver, Antigenic and biological characterization of influenza virus neuraminidase (N2) with monoclonal antibodies. Virology, 1984. 135(1): p. 30-42. 80. Palese, P., et al., Characterization of temperature sensitive influenza virus mutants defective in neuraminidase. Virology, 1974. 61(2): p. 397-410. 81. Cohen, M., et al., Influenza A penetrates host mucus by cleaving sialic acids with neuraminidase. Virol J, 2013. 10: p. 321. 82. Hooper, K.A. and J.D. Bloom, A mutant influenza virus that uses an N1 neuraminidase as the receptor-binding protein. J Virol, 2013. 87(23): p. 12531-40. 83. Hu, Y., et al., Association between adverse clinical outcome in human disease caused by novel influenza A H7N9 virus and sustained viral shedding and emergence of antiviral resistance. The Lancet, 2013. 381(9885): p. 2273-2279. 84. Yang, J., et al., A new role of neuraminidase (NA) in the influenza virus life cycle: implication for developing NA inhibitors with novel mechanism of action. Rev Med Virol, 2016. 85. Schultz-Cherry S, H.V., Influenza virus neuraminidase activates latent transforming growth factor beta. J Virol, 1996. 70: p. 8624-8629. 86. Fouchier, R.A.M., et al., Transforming growth factor-β: Activation by neuraminidase and role in highly pathogenic H5N1 influenza pathogenesis. PLoS Pathogens, 2010. 6(10): p. e1001136. 87. Skountzou, I., et al., Influenza virus-specific neutralizing IgM antibodies persist for a lifetime. Clin Vaccine Immunol, 2014. 21(11): p. 1481-9. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/49362 | - |
dc.description.abstract | 2013年中國爆發人類感染H7N9禽流感疫情,經分析此新型流感病毒後發現,其基因片段由數種低病原性病毒 (low-pathogenicity avian influenza, LPAI),重排 (reassortant) 而來。禽鳥為H7N9之自然保毒者 (reservoir),染病後並無明顯病徵,疫情監控相對不易。人類主要感染途徑為接觸帶原禽鳥,受感染人類重症率及死亡率都相當高,且台灣曾有4名境外移入病例,故發展快速篩檢平台成為防疫之重要的議題。流感病毒表面之神經胺酸酶 (neuraminidase, NA) 為重要表面抗原,與血球凝集素 (hemagglutinin, HA) 在不同亞型間皆有高度的變異性。同時NA帶有切割唾液酸與半乳糖間醣苷鍵的酵素催化活性,在病毒散播上為最主要的推手,更是目前開發抗流感藥物與作為病毒篩檢之抗原標的。本研究目標在於針對H7N9之NA製備抑制性單株抗體,並期望此單株抗體能投入篩檢平台之開發,協助H7N9疫情監控。本研究嘗試兩種抗原免疫策略,其一利用軟體預測NA序列上,適合之胜肽片段作為抗原 (NA-1、NA-2及NA-3),其二乃利用桿狀病毒-昆蟲細胞表現系統,表現N9NA球狀頭部區域重組蛋白作為抗原,分別進行小鼠免疫以製備單株抗體。結果顯示,策略一以NA-3胜肽片段製備得可辨認N9NA重組蛋白之單株抗體,而策略二,最終篩得兩株抗NA單株抗體。經抗體分型試驗,確認此三株抗體皆為IgM。進一步由enzyme linked lectin assay (ELLA) 評估抗體對NA切割醣類之抑制能力,結果發現,策略一以NA-3胜肽片段製備之單株抗體 (1B11),無抑制NA活性之能力,後續將再針對策略二所得之單株抗體進行分析,期望能得到具有抑制NA活性之單株抗體,將有助於了解NA對宿主的致病機轉。未來更期望單株抗體能投入臨床診斷平台之開發,達到疫情監控及防疫之目的。 | zh_TW |
dc.description.abstract | In March 2013, the first case of human infections caused by avian-origin H7N9 subtype influenza A virus was confirmed in China. H7N9 was reasserted form a variety of low-pathogenicity avian influenza (LPAI) viruses. In contrast to mild symptoms shown on infected birds, the main reservoir of H7N9 virus, human infections resulted in severe respiratory illness and high mortality. In Taiwan, four patients were confirmed as H7N9 infection cases after returning from China. Therefore, it is a critical issue to improve surveillance of influenza and develop quick clinical diagnosis platform for H7N9. The hypervariable surface glycoproteins, hemagglutinin (HA) and neuraminidase (NA), of influenza viruses among different subtypes could serve as good targets for developing monoclonal antibody (mAb) against H7N9 virus. In this study, two strategies were utilized for preparation of NA mAb. One is to immunize mice with synthetic peptides (NA-1, NA-2 and NA-3) derived from H7N9 NA, the other is using recombinant N9NA (rN9NA) expressed by baculovirus. Only NA-3 showed relatively high immunogenicity among these peptides, and the antisera derived from NA-3 could recognize rN9NA. After six boosts, mice were sacrificed to prepared hybridoma. One mAb against NA-3 (1B11) and two mAb against rN9NA (2F08 and 3G08) with high specificity were isolated from strategy1 and strategy2, respectively. All the selected mAb are IgM having κ light chain. Analyzed by enzyme-linked lectin assay (ELLA), mAb 1B11 was found not a NA inhibiting antibody. The NA inhibition for the two mAb derived from strategy 2 will be evaluated with ELLA. Once the NA inhibition capacity of the mAb was verified, these mAb will be applied to the development of clinical diagnose platform for H7N9, such as blocking ELISA and antigen-capture ELISA, in the hope of strengthening the surveillance of influenza virus and disease control in Taiwan. | en |
dc.description.provenance | Made available in DSpace on 2021-06-15T11:25:18Z (GMT). No. of bitstreams: 1 ntu-105-R03b22051-1.pdf: 6763716 bytes, checksum: 8546c161840964fef1534a7694705a50 (MD5) Previous issue date: 2016 | en |
dc.description.tableofcontents | 中文摘要 iii
Abstract iv 縮寫表 vi 第一章 緒論 1 1.1流行性感冒病毒 1 1.1.1流感病毒的歷史背景 1 1.1.2流感病毒之分類 2 1.1.3流感病毒之構造及形態 3 1.1.4流感病毒之基因體 4 1.1.5流感病毒蛋白質功能簡介 5 1.1.6流感病毒生活史及複製週期 7 1.1.7流感病毒之變異 11 1.2新型H7N9流感病毒 12 1.2.1新型H7N9流感病例爆發 12 1.2.2新型H7N9流感病毒介紹 13 1.2.3新型H7N9流感病毒蛋白質序列特性 14 1.3 神經胺酸酶 (neuraminidase, NA) 16 1.3.1NA的結構 16 1.3.2 NA之酵素催化活性 17 1.3.3 NA抑制劑與NA之抗藥性 20 1.3.4 NA為流感病毒重要的表面抗原 20 1.3.5 NA所扮演角色 21 1.4研究動機及目的 23 第二章 材料方法 24 2.1 抗原決定基之預測 24 2.2 N9NA重組蛋白之製備 25 2.2.1 表現載體及重組昆蟲桿狀病毒之製備 25 2.2.2 重組蛋白之表現純化 28 2.3 傳統抗血清及單株抗體之製備 30 2.3.1 小鼠免疫 30 2.3.2 傳統抗血清製備 30 2.3.3 融合瘤之製備 30 2.3.4 腹水誘導及單株抗體製備 33 2.4 免疫學方法 34 2.4.1 Enzyme-linked immunosorbent assay (ELISA) 34 2.4.2 單株抗體型別分析 (Isotyping) 34 2.4.3 西方墨點法 (Western blot) 35 2.5 神經胺酸酶活性測試及活性抑制測試 35 2.5.1 NA活性測試 (Enzyme linked lectin assay, ELLA) 35 2.5.2 NA inhibition assay 36 2.6 蛋白質身份鑑定 36 2.6.1 前處理 36 2.6.2 膠體內蛋白酶水解 37 第三章 結果與討論 38 3.1挑選胜肽片段做為抗原 38 3.1.1流感NA亞型之序列比對 38 3.1.2 抗原性預測及後修飾預測 39 3.1.3 確認胜肽抗原於NA立體結構之位置 40 3.2重組蛋白之製備 48 3.2.1 以大腸桿菌系統表現N9NA 48 3.2.2 以桿狀病毒-昆蟲細胞系統表現N9NA 49 3.3抗體之製備 57 3.3.1 小鼠免疫及血清效價測試 57 3.3.2 融合瘤與單株抗體篩選 58 3.3.3 單株抗體之正負向篩選 59 3.3.4單株抗體分型 (Isotyping) 60 3.4以Enzyme linked lectin assay (ELLA) 測試抗體對NA之抑制能力 75 第四章 結論 80 參考文獻 82 問答錄 88 | |
dc.language.iso | zh-TW | |
dc.title | H7N9流感病毒神經胺酸酶單株抗體之製備及檢測平台開發 | zh_TW |
dc.title | Development of monoclonal antibodies against the neuraminidase of H7N9 influenza virus for diagnosis applications | en |
dc.type | Thesis | |
dc.date.schoolyear | 104-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 張明富,張世宗,陳翰民,陳慧文 | |
dc.subject.keyword | A型流感病毒,禽流感,神經胺酸?,單株抗體,H7N9, | zh_TW |
dc.subject.keyword | influenza A virus, avian influenza,neuraminidase,monoclonal antibody,H7N9, | en |
dc.relation.page | 92 | |
dc.identifier.doi | 10.6342/NTU201602870 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2016-08-18 | |
dc.contributor.author-college | 生命科學院 | zh_TW |
dc.contributor.author-dept | 生化科技學系 | zh_TW |
顯示於系所單位: | 生化科技學系 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-105-1.pdf 目前未授權公開取用 | 6.61 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。